Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Bush

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Journal of Medicinal Chemistry|March 4, 1994
In vitro and in vivo activities of reduced-size antagonists of luteinizing hormone-releasing hormoneF Haviv, T D Fitzpatrick, C J Nichols, et al.
Journal of Medicinal Chemistry|October 16, 1992
Stabilization of the N-terminal residues of luteinizing hormone-releasing hormone agonists and the effect on pharmacokineticsF Haviy, T D Fitzpatrick, C J Nichols, et al.
Journal of Medicinal Chemistry|February 5, 1993
Effect of N-methyl substitution of the peptide bonds in luteinizing hormone-releasing hormone agonistsF Haviv, T D Fitzpatrick, R E Swenson, et al.
Cell Metabolism|October 18, 2016
Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to MetforminDan Y Gui, Lucas B Sullivan, Alba Luengo, et al.
Journal of Medicinal Chemistry|April 2, 1993
The effect of NMeTyr5 substitution in luteinizing hormone-releasing hormone antagonistsF Haviv, T D Fitzpatrick, C J Nichols, et al.
Dermatology and Therapy|September 2, 2015
A Qualitative Comparison of Symptoms and Impact of Varying Stages of Basal Cell CarcinomaAnna W Steenrod, Emily Nash Smyth, Elizabeth N Bush, et al.
Oncology Nursing Forum|January 1, 1997
Quality of life and the cancer experience: the state-of-the-knowledgeC R King, M Haberman, D L Berry, et al.
Nature Cell Biology|June 27, 2018
Aspartate is an endogenous metabolic limitation for tumour growthLucas B Sullivan, Alba Luengo, Laura V Danai, et al.
Journal of Medicinal Chemistry|March 16, 1992
Small atrial natriuretic peptide analogues: design, synthesis, and structural requirements for guanylate cyclase activationT W von Geldern, T W Rockway, S K Davidsen, et al.
Journal of Medicinal Chemistry|February 20, 2004
Nonpeptide luteinizing hormone-releasing hormone antagonists derived from erythromycin A: design, synthesis, and biological activity of cladinose replacement analoguesJohn T Randolph, Philip Waid, Charles Nichols, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Journal of Medicinal Chemistry|March 4, 1994
In vitro and in vivo activities of reduced-size antagonists of luteinizing hormone-releasing hormoneF Haviv, T D Fitzpatrick, C J Nichols, et al.
Journal of Medicinal Chemistry|October 16, 1992
Stabilization of the N-terminal residues of luteinizing hormone-releasing hormone agonists and the effect on pharmacokineticsF Haviy, T D Fitzpatrick, C J Nichols, et al.
Journal of Medicinal Chemistry|February 5, 1993
Effect of N-methyl substitution of the peptide bonds in luteinizing hormone-releasing hormone agonistsF Haviv, T D Fitzpatrick, R E Swenson, et al.
Cell Metabolism|October 18, 2016
Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to MetforminDan Y Gui, Lucas B Sullivan, Alba Luengo, et al.
Journal of Medicinal Chemistry|April 2, 1993
The effect of NMeTyr5 substitution in luteinizing hormone-releasing hormone antagonistsF Haviv, T D Fitzpatrick, C J Nichols, et al.
Dermatology and Therapy|September 2, 2015
A Qualitative Comparison of Symptoms and Impact of Varying Stages of Basal Cell CarcinomaAnna W Steenrod, Emily Nash Smyth, Elizabeth N Bush, et al.
Oncology Nursing Forum|January 1, 1997
Quality of life and the cancer experience: the state-of-the-knowledgeC R King, M Haberman, D L Berry, et al.
Nature Cell Biology|June 27, 2018
Aspartate is an endogenous metabolic limitation for tumour growthLucas B Sullivan, Alba Luengo, Laura V Danai, et al.
Journal of Medicinal Chemistry|March 16, 1992
Small atrial natriuretic peptide analogues: design, synthesis, and structural requirements for guanylate cyclase activationT W von Geldern, T W Rockway, S K Davidsen, et al.
Journal of Medicinal Chemistry|February 20, 2004
Nonpeptide luteinizing hormone-releasing hormone antagonists derived from erythromycin A: design, synthesis, and biological activity of cladinose replacement analoguesJohn T Randolph, Philip Waid, Charles Nichols, et al.
Pageof 9